Áttétes emlőrák: vizsgálatok itt: Spanyolország
73 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisNot yet taking people in SpanyolországA clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
- Where
- Madrid, Valencia
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522707-26-00 - 1/2. fázisNot yet taking people in SpanyolországA Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
- Where
- Barcelona, Madrid, Pamplona
- Életkor
- 18 év to 64 év
- People
- 18
- Run by
- Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
See details and how to join2026-527365-30-00 - 2. fázisNot yet taking people in SpanyolországEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- A Coruña, Barcelona, Bilbao, Granada, Jaén, Madrid, Málaga, Zaragoza
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 3. fázisNot yet taking people in SpanyolországA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Where
- Badajoz, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Huelva, Jaén, Las Palmas de Gran Canaria, Majadahonda, Málaga, Murcia, Oviedo, Palma de Mallorca, Pontevedra, Pozuelo de Alarcón, Santander, Toledo, Zaragoza
- Életkor
- 18 év to 130 év
- People
- 150 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07647328 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Barcelona, Córdoba, Madrid, Pozuelo de Alarcón, Seville, Valencia
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - 1/2. fázisTaking peopleTo compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 73 worldwide
- Run by
- Genentech Inc.
See details and how to join2025-521128-31-00 - 3. fázisNot yet taking people in SpanyolországPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- A Coruña, Badajoz, Barcelona, Cáceres, L'Hospitalet de Llobregat, Lleida, Madrid, Murcia, Santiago de Compostela, Valencia
- Életkor
- 18 év and over
- People
- 1180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - No phaseTaking peopleA Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
- Where
- A Coruña, Albacete, Alcorcón, Alicante, Ávila, Barcelona, Bilbao, Córdoba, Elche, Fuenlabrada, Las Palmas de Gran Canaria, Leganés, León, Lugo, Madrid, Málaga, Manresa, Murcia, Palma de Mallorca, Pamplona, Sagunto, Salamanca, San Sebastián, San Sebastián de los Reyes, Santa Cruz de Tenerife, Seville, Terrassa, Toledo, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 1867
- Run by
- Spanish Breast Cancer Research Group
See details and how to joinNCT02819882 - 2. fázisTaking peoplePhase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 100
- Run by
- TNC Nutrición Terapéutica S.L.
See details and how to joinNCT07406789 - 2. fázisTaking peopleA TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
- Where
- Barcelona, Bilbao, Córdoba, Elche, Girona, L'Hospitalet de Llobregat, Lleida, Madrid, Málaga, Palma, Reus, Santander, Sant Cugat del Vallès, Santiago De Compostela, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 25 worldwide
- Run by
- Medica Scientia Innovation Research S.L.
See details and how to join2026-525328-10-00 - 1/2. fázisTaking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Sevilla
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1. fázisTaking peoplePhase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193 - 3. fázisTaking peopleA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Where
- Barcelona, Coruña, Granada, Madrid, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07205822 · EU 2025-521904-23-00 - 2. fázisTaking peopleA Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Where
- Alicante, Barakaldo, Barcelona, Bilbao, Cáceres, Granada, Huelva, Jaén, Lleida, Madrid, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 225 worldwide
- Run by
- Puma Biotechnology, Inc.
See details and how to joinNCT06369285 · EU 2024-511497-79-00 - 1. fázisTaking peopleOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Where
- Barcelona, Lleida, Madrid, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 392 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00 - 1/2. fázisNot yet taking people in SpanyolországA Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Where
- Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife, Santiago de Compostela, Seville
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Alicante, Barcelona, Granada, León, Lleida, Madrid, Murcia, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - 2. fázisNot yet taking people in SpanyolországRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Where
- Barcelona, Madrid
- People
- 51 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07679269 · EU 2026-525890-38-00 - 1. fázisNot yet taking people in SpanyolországA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Barcelona, L'Hospitalet de Llobregat
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Pamplona
- Életkor
- 18 év and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - 2. fázisTaking peopleLuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
- Where
- A Coruña, Badalona, Madrid
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - 3. fázisTaking peopleElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- A Coruna, Alicante, Alzira, Badalona, Barcelona, Bilbao, Burgos, Cáceres, Castello De La Plana, Granada, Jaén, Las Palmas de Gran Canaria, León, Lleida, Madrid, Majadahonda, Murcia, Palma, Pamplona, Reus, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Sant Joan d'Alacant, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseNot yet taking people in SpanyolországDESTINY Breast Respond HER2-(Ultra)Low Europe
- Where
- Albacete, Alicante, Alzira, Barakaldo, Barcelona, Bilbao, Cáceres, Cadiz, Córdoba, Elche, Galdakao, Granada, Jaén, León, Logroño, Lugo, Madrid, Murcia, Oviedo, Palencia, Palma, Palma de Mallorca, Pontevedra, Reus, Sabadell, Salamanca, San Cristóbal de La Laguna, Santander, Sant Cugat del Vallès, Valencia, Valladolid, Vigo Pontevedra, Zaragoza
- Életkor
- 18 év and over
- People
- 2295 worldwide
- Run by
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732